In particular, the Proactive Molecular Risk Classifier for Endometrial cancers (ProMisE), which is based on three key components: immunohistochemistry (IHC) for the presence of mismatch repair (MMR) proteins, sequencing for the presence of POLE exonuclease domain mutations (EDMs) and IHC for p53 [52]. This evidence concerns the gene POLE and endometrial cancer.